Get the Stockscreener App
2.3346
0.00%
-0.0046
Fate Therapeutics Inc stock is traded at $2.3346, with a volume of 168.52K.
It is down -0.00% in the last 24 hours and down -8.63% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$2.33
Open:
$2.34
24h Volume:
168.52K
Relative Volume:
0.06
Market Cap:
$280.38M
Revenue:
$6.65M
Net Income/Loss:
$-136.32M
P/E Ratio:
-2.0342
EPS:
-1.1477
Net Cash Flow:
$-112.04M
1W Performance:
-7.91%
1M Performance:
-8.63%
6M Performance:
+90.98%
1Y Performance:
+140.00%
1-Day Range:
$2.27
$2.35
1-Week Range:
$2.27
$2.63
52-Week Range:
$0.95
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.34 | 279.18M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
521.26 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.50 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.78 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.03 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.36 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-26 | Resumed | Jefferies | Buy |
| Oct-31-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-27-25 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Canada
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - quiverquant.com
Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - Yahoo Finance UK
Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada
FATE: Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis - TradingView
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative
FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics Announces Encore Clinical Data - GlobeNewswire
Fate Therapeutics Market Sentiment - Benzinga España
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Fate Therapeutics stock holds steady as investors watch cash runway and pipeline - ad-hoc-news.de
FATE Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusPost-Earnings Drift - vinanet.vn
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - Yahoo Finance
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics stock stabilizes after autoimmune CAR-T safety shock - ad-hoc-news.de
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE) - Seeking Alpha
574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC - marketbeat.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
symbol__ Stock Quote Price and Forecast - CNN
Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et
Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn
Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International
Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com
Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView
Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative
Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan
FATE THERAPEUTICSPATIENTS TO RECEIVE SINGLE 900 MLN-CELL DOSE OF FT819; PRIMARY ENDPOINT AT WEEK 26 - webull.com
FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget
Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo! Finance Canada
Fate Therapeutics Reports Q2 2026 10-Q Filing Highlighting iPSC Pipeline and Key Risks - Kalkine Media
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Fate Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):